TY - JOUR
T1 - Barriers to sexual recovery in women with urologic cancers
AU - Vencill, Jennifer A.
AU - Kacel, Elizabeth L.
AU - Avulova, Svetlana
AU - Ehlers, Shawna L.
N1 - Funding Information:
No other persons have made substantial contributions to this manuscript. Funding Sources: There are no funding sources to disclose.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2022/8
Y1 - 2022/8
N2 - Sexual health concerns are prevalent and distressing in oncology patients and survivors. While urologic cancers are more prevalent in men, women often have more advanced disease at initial diagnosis, require more advanced surgical resection, and experience higher postoperative complication rates, as well as morbidity and mortality. Women with urologic cancers undergo treatment that is highly likely to impact their sexual function and well-being, however, attention to sexual recovery in this patient population has been limited. Barriers to sexual recovery in women with urologic cancers are biopsychosocial in nature and include complications related to treatment procedures, cancer-related distress, sexual anxiety and avoidance, partner and relational dynamics, and sexual communication skills. Healthcare providers do not adequately address sexual difficulties for these patients and their partners. Sexual minority women and transgender patients with urologic cancer have unique psychosocial and sexual health needs though, due to a lack of research, these remain poorly understood. More research is needed to pinpoint the sexual health needs of this specific oncology population and to explore how various treatment options, such as pelvic organ-sparing cystectomy, can impact sexual health outcomes. Evidence-based and multidisciplinary oncologic and survivorship care, which includes licensed mental health providers, certified sex therapists, and other sexual health experts, is essential for assisting women in their sexual recovery following urologic cancer.
AB - Sexual health concerns are prevalent and distressing in oncology patients and survivors. While urologic cancers are more prevalent in men, women often have more advanced disease at initial diagnosis, require more advanced surgical resection, and experience higher postoperative complication rates, as well as morbidity and mortality. Women with urologic cancers undergo treatment that is highly likely to impact their sexual function and well-being, however, attention to sexual recovery in this patient population has been limited. Barriers to sexual recovery in women with urologic cancers are biopsychosocial in nature and include complications related to treatment procedures, cancer-related distress, sexual anxiety and avoidance, partner and relational dynamics, and sexual communication skills. Healthcare providers do not adequately address sexual difficulties for these patients and their partners. Sexual minority women and transgender patients with urologic cancer have unique psychosocial and sexual health needs though, due to a lack of research, these remain poorly understood. More research is needed to pinpoint the sexual health needs of this specific oncology population and to explore how various treatment options, such as pelvic organ-sparing cystectomy, can impact sexual health outcomes. Evidence-based and multidisciplinary oncologic and survivorship care, which includes licensed mental health providers, certified sex therapists, and other sexual health experts, is essential for assisting women in their sexual recovery following urologic cancer.
KW - Bladder cancer
KW - Cancer survivorship
KW - Cystectomy
KW - Genitourinary cancer
KW - Genitourinary syndrome of menopause
KW - Kidney cancer
KW - Quality of life
KW - Sexual dysfunction
KW - Sexual function
KW - Sexual health
KW - Sexual recovery
KW - Urologic cancer
UR - http://www.scopus.com/inward/record.url?scp=85096822355&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096822355&partnerID=8YFLogxK
U2 - 10.1016/j.urolonc.2020.11.011
DO - 10.1016/j.urolonc.2020.11.011
M3 - Review article
C2 - 33248897
AN - SCOPUS:85096822355
SN - 1078-1439
VL - 40
SP - 372
EP - 378
JO - Urologic Oncology: Seminars and Original Investigations
JF - Urologic Oncology: Seminars and Original Investigations
IS - 8
ER -